Compare Ginkgo Bioworks Holdings Inc (DNA) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Nutanix Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.95 (market cap $763.64M), while Nutanix Inc trades at $74.59 (market cap $19.78B). The key difference: Nutanix Inc is far larger — about 25.9× Ginkgo Bioworks Holdings Inc's market cap, and Nutanix Inc is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Nutanix Inc for 17 Days on average.
| DNA | NTNX | |
|---|---|---|
Market Cap | $763.64M | $19.78B |
Volume | 3,204,177 | 1,717,619 |
Sector | Health | Technology |
52-Week High | $15.83 | $73.42 |
52-Week Low | $5.48 | $34.41 |
Typical Hold Time | 7 Days | 17 Days |
Enterprise Value | $865.59M | $18.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.00, up 13.34% today, with a bullish technical signal from moving averages. The company shows strong gross margins of 68.04% but remains unprofitable with a -219.6% net margin. Recent news includes a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnership expansions, though revenue declined to $132M in 2026.
DNA presents high risk with significant losses and cash burn, but analyst sentiment is divided with equal buy/sell ratings. Investment appeal hinges on future profitability from recent partnerships and government contracts, while current financials and negative cash flow pose substantial downside risk.
Nutanix (NTNX) trades at $74.63, up 1.65% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported robust revenue growth to $2.54B in 2025 and a net income margin of 52.81% in 2026, supported by leadership recognition in Gartner Magic Quadrant reports (GlobeNewsWire, 2026-09-16).
Outlook remains positive with a consensus price target of $76.11, though high valuation ratios like EV/EBITDA of 46.22 and an overbought RSI near 89.09 pose risks. Growth drivers include external storage and AI initiatives, but investor caution is warranted due to competitive pressures and supply-chain constraints noted in recent news (MarketBeat, 2026-09-14).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
